USPTO serial 79448229
RESILIOME
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUNN, MADELINE R
- Law office
- TMO LAW OFFICE 132
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with RESILIOME?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical preparations for scientific or research purposes, other than for medical use; antibodies for scientific or research purposes, other than for medical use; diagnostic preparations for scientific or research purposes, other than for medical use. | ACTIVE | — |
| 005 | Pharmaceutical preparations; medicines for human purposes; pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disorders, metabolic diseases and disorders, immunological diseases and disorders, oncological diseases and disorders, Amyotrophic Lateral Sclerosis (ALS), muscle atrophy, Parkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes. | ACTIVE | — |
| 009 | Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology. | ACTIVE | — |
| 042 | Scientific and technological services; research and development services; research and development services in the field of antibodies and antibody technology; drug development services; drug discovery services; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery and identification services; antibody discovery services for the purpose of drug discovery; research in the field of biomarkers; research and development in the field of pharmaceuticals; research and development in the field of diagnostic preparations; clinical research; clinical trials; development and testing of computing methods, algorithms and software in biotechnology and medical fields, including antibody technology; development and testing of computing methods, algorithms and software for the testing and identification of antibodies; development and testing of computing methods, algorithms and software relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; platforms as a service [PaaS] and software as a service [SaaS] in the field of medicine discovery; information, advisory and consultancy services in relation to all of the aforesaid. | ACTIVE | — |
| 044 | Medical testing for diagnostic or treatment purposes; medical diagnostic services; medical analysis for diagnostic and treatment purposes; medical testing, analysis and diagnostic services in the field of antibodies and biomarkers; medical diagnostic services involving the testing of antibodies for medical purposes; analysis and identification of antibody data for medical and diagnostic purposes; information, advisory and consultancy services in relation to all of the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alchemab Therapeutics Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RESILIOME
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 29, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 29, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 20, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 19, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 18, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 16, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |